The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent

JACC: Cardiovascular Interventions

Volumn 6, Issue 4, 2013, Pages 325-333

  Kirtane, Ajay J ^a   Leon, Martin B ^a   Ball, Michael W ^b   Bajwa, Harpaul S ^c   Sketch Jr , Michael H ^d   Coleman, Patrick S ^e   Stoler, Robert C ^f   Papadakos, Stylianos ^g   Cutlip, Donald E ^h   Mauri, Laura ⁱ   Kandzari, David E ^j  

^a NewYork Presbyterian Hospital   (United States)

^b St Vincent s Heart Center of Indiana   (United States)

^c Nebraska Heart Institute   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Sutter Medical Center   (United States)

^f BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^g LENOX HILL HEART AND VASCULAR INSTITUTE   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j PIEDMONT HEART INSTITUTE   (United States)

more..

Author keywords

coronary artery disease; paclitaxel eluting stent; zotarolimus eluting stent

Indexed keywords

PACLITAXEL; ZOTAROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; STENT THROMBOSIS; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK FACTORS; SINGLE-BLIND METHOD; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84876413538     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2012.12.123     Document Type: Article

References (28)

1. G.W. Stone, S.G. Ellis, D.A. Cox A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
2. J.W. Moses, M.B. Leon, J.J. Popma Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
3. L. Mauri, W.H. Hsieh, J.M. Massaro, K.K. Ho, R. D'Agostino, D.E. Cutlip Stent thrombosis in randomized clinical trials of drug-eluting stents N Engl J Med 356 2007 1020 1029
4. A.J. Kirtane, A. Gupta, S. Iyengar Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies Circulation 119 2009 3198 3206
5. P. Wenaweser, J. Daemen, M. Zwahlen Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice 4-year results from a large 2-institutional cohort study J Am Coll Cardiol 52 2008 1134 1140
6. E.P. McFadden, E. Stabile, E. Regar Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy Lancet 364 2004 1519 1521
7. L. Räber, L. Wohlwend, M. Wigger Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial Circulation 123 2011 2819 2828 6 following 2828
8. M.B. Leon, L. Mauri, J.J. Popma A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial J Am Coll Cardiol 55 2010 543 554
9. M.B. Leon, E. Nikolsky, D.E. Cutlip Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease) trial J Am Coll Cardiol Intv 3 2010 1043 1050
10. M.B. Leon, D.E. Kandzari, E.L. Eisenstein Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic ENDEAVOR Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) J Am Coll Cardiol Intv 2 2009 1208 1218
11. D.E. Cutlip, S. Windecker, R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
12. D.M. Whelan, W.J. van der Giessen, S.C. Krabbendam Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries Heart 83 2000 338 345
13. I.T. Meredith, S. Worthley, R. Whitbourn Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial J Am Coll Cardiol Intv 2 2009 977 985
14. D.E. Kandzari, L. Mauri, J.J. Popma Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents 5-Year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic ENDEAVOR Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) J Am Coll Cardiol Intv 4 2011 543 550
15. A.V. Finn, G. Nakazawa, M. Joner Vascular responses to drug eluting stents: importance of delayed healing Arterioscler Thromb Vasc Biol 27 2007 1500 1510
16. G. Nakazawa, A.V. Finn, M.C. John, F.D. Kolodgie, R. Virmani The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents Am J Cardiol 100 2007 36M 44M
17. A. Miyazawa, J. Ako, Y. Hongo Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III Am Heart J 155 2008 108 113
18. M. Awata, S. Nanto, M. Uematsu Angioscopic comparison of neointimal coverage between zotarolimus- and sirolimus-eluting stents J Am Coll Cardiol 52 2008 789 790
19. D.I. Shin, K.B. Seung, P.J. Kim Long-term coronary endothelial function after zotarolimus-eluting stent implantation A 9 month comparison between zotarolimus-eluting and sirolimus-eluting stents Int Heart J 49 2008 639 652
20. J.S. Kim, I.K. Jang, C. Fan Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial J Am Coll Cardiol Intv 2 2009 1240 1247
21. L. Mauri, J.M. Massaro, S. Jiang Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents J Am Coll Cardiol Intv 3 2010 1240 1249
22. J.J. Popma, L. Mauri, C. O'Shaughnessy Frequency and clinical consequences associated with sidebranch occlusion during stent implantation using zotarolimus-eluting and paclitaxel-eluting coronary stents Circ Cardiovasc Interv 2 2009 133 139
23. P. Garg, D.J. Cohen, T. Gaziano, L. Mauri Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model J Am Coll Cardiol 51 2008 1844 1853
24. G.G. Stefanini, B. Kalesan, P.W. Serruys Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial Lancet 378 2011 1940 1948
25. L. Räber, M. Magro, G.G. Stefanini Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study Circulation 125 2012 1110 1121
26. M. Valgimigli, G. Campo, M. Monti Short-versus long-term duration of dual antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 2012 2015 2026
27. S.J. Park, D.W. Park, Y.H. Kim Duration of dual antiplatelet therapy after implantation of drug-eluting stents N Engl J Med 362 2010 1374 1382
28. E. Camenzind, W. Wijns, L. Mauri Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial Lancet 380 2012 1396 1405